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ABSTRACT
BACKGROUND: Cholecystokinin (CCK) has been found to be a growth stimu-
lant through its special receptor pathway, especially for gastrointestinal malignancies,
Although the CCK-l receptor has been shown to be highly expressed in resected hu-
man pancreatic cancer samples, its role is less clear.
OBJECTIVE: The aim of this in vitro study was to investigate the CCK-1 recep-
tor expression and the function of the CCK-CCK-l receptor pathway in the human
pancreatic adenocarcinoma cell line, Mia PaCa-2.
METHODS: The expression of the CCK-1 receptor in Mia PaCa-2 cells was de-
tected by reverse-transcriptase polymerase chain reaction and flow cytometry. CCK-1
receptor agonist CCK-8S (the major transmitter form of CCK) and antagonist lorglu-
mide were cultured respectively with Mia PaCa-2. Three groups were created for this
study: CCK-8S group (Mia PaCa-2 cells treated with CCK-8S), lorglumide group
(Mia PaCa-2 cells treated with lorglumide), and the control group (Mia PaCa-2 cells
alone). Investigators were blinded to group designation. 3-[4,5-Dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide (MTT) and flow cytometry were used to detect
the cell growth, cell cycle, and apoptosis. Apoptosis index rate was measured by ter-
minal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end la-
beling. Cell invasion ability was observed by invasion assay. Expression of matrix
metalloproteinase-2 (MMP-2) was measured by Western blotting.
RESULTS: Mia PaCa-2 cells were found to express the CCK-l receptor. Compared
with the control group (70.2% [l.5%}), CCK-8S was associated with significant mean
(SD) cell proliferation (85.1% [l.7%}; P = 0.039), and the ratio in the S stage of the
cell cycle increased significantly (50.5% [l.7%} vs 42.2% [l.4%}; P = 0.021). CCK-8S
was also associated with increased Mia PaCa-2 cell invasion ability (123.8 [l.7} vs
102.1 [5 .8}; P = 0.005 vs control). Compared with the control group, lorglumide was
associated with significantly inhibited cell growth (52.1% [l.8%}; P = 0.002) and
cell invasion (77.6% [l.2%}; P = 0.003). Lorglumide also induced GO/G1 cell cyclearrest
and apoptosis (27.1% [3.5%} vs 3.7% [0.6%}; P = 0.003 vs control). The change of
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invasion ability appeared to be mediated by MMP-2 expression, which was upregu-
lated by CCK-8S and downregulated by lorglumide.
CONCLUSION: The findings of this in vitro study suggest that CCK may exert a
trophic action on the Mia PaCa-2 cell line, while lorglumide inhibited the cell growth
and invasion. (Curr Tber Res ClinExp. 2010;71:239-251) © 2010 Excerpta Medica Inc.
KEY WORDS: cholecystokinin, CCK-1 receptor, pancreatic cancer, apoptosis,
MMP-2.
INTRODUCTION
Pancreatic cancer remains a challenge to clinicians. The anatomic complexity and late
diagnosis have led to a low resectability rate of -10% to 20%, especially in pancreatic
cancer centers. l Moreover, even if it is possible to resect the tumor with a clear margin,
early recurrence and metastasis are frequently observed.r' The overall 5-year survival
rates are reported to be < 5%.
New approaches, including gene therapy and chemotherapeutic drugs, are required
to improve treatment resulrs.v One such approach might be hormonal therapy, which
is widely accepted as the standard treatment for breast, prostate, and differentiated
thyroid cancers.v "
Cholecystokinin (CCK) is a gastrointestinal peptide hormone known to stimulate
postprandial gallbladder contraction and pancreatic enzyme secretion'? Gastrin is struc-
turally related to CCK. Receptors of CCK are considered to contain CCK-l receptor,
CCK-2/gastrin receptor, CCK-3 receptor, and other hyporypes." While exerting the
aforementioned classic actions, CCK and gastrin are also considered to act as growth
stimulants via the CCK-2-gastrin receptor pathway, especially for gastrointestinal ma-
lignancies.? Several cell lines of evidence suggest that CCK/gastrin and the CCK-2 re-
ceptor contribute to pancreatic carcinogenesis by modulating processes such as prolifera-
tion and cell adhesion or migration.l'v'! 2-360, a novel orally available CCK-2 receptor
antagonist, may be a useful adjunct to gemcitabine for treatment of advanced pancreatic
cancer.12,13 Besides the receptor-targeted treatment, the use of the CCK-2 receptor for
tumor imaging and radiotherapy has been studied in recent years.14,15
Although the CCK-1 receptor has been found to be highly expressed in resected
human pancreatic cancer sarnples.l'' the mechanism between the CCK-CCK-1 recep-
tor pathway and pancreatic cancer is still unclear. We were, therefore, interested in
whether the CCK-1 receptor is expressed in the pancreatic cancer cell line and which
function is involved in pancreatic cancer via the receptor pathway.
MATERIALS AND METHODS
STUDY DESIGN
CCK-8S, the major transmitter form of CCK, was used as the CCK-1 receptor
agonist and lorglumide as the receptor antagonist in our study. Three groups were
created for this study: CCK-8S group (Mia PaCa-2 cells treated with CCK-8S), lor-
glumide group (Mia PaCa-2 cells treated with lorglumide), and the control group
(Mia PaCa-2 cells alone).
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CELLS, CULTURE MEDIUM, CHEMICALS, AND ANTIBODIES
The Mia PaCa-2 cell line was obtained from American Type Culture Collection
(Manassas, Virginia). The cells were cultured in adherent Dulbecco's Modified Eagle's
Medium (DMEM) supplemented with 10% fetal bovine serum at 37°C, in a humidi-
fied atmosphere of 5% carbon dioxide in air. The cultures were passaged 2 or 3 times
weekly to maintain log-phase growth.
CCK-8S, lorglumide, and 3-[4,5-dimethylthiazol-2-yl}-2,5-diphenyltetrazolium
bromide (MTT) were purchased from Sigma Chemical Co. (St. louis, Missouri) and
were diluted under specification. Polymerase chain reaction (PCR) primers were syn-
thesized by Shanghai Sangon Biotech Co. (Shanghai, China). TRIzol reagent was
purchased from Invitrogen (Carlsbad, California). The fluorescein isothiocyanate anti-
human CCK-1 receptor monoclonal antibody was purchased from Shanghai Jingmei
Biotech Co. (Shanghai, China). The BD ApoAlert DNA fragmentation assay was pur-
chased from Clontech laboratories, Inc. (Palo Alto, California). Apoptosis was as-
sessed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate
nick-end labeling (TUNEl) using an in situ cell death detection kit purchased from
Roche (Shanghai, China). Transwell was purchased from Corning Incorporated (Corn-
ing, New York). Matrigel and fibronectin were purchased from Becton, Dickinson and
Company (Franklin lakes, New Jersey). Matrix metalloproteinase-2 (MMP-2) mono-
clonal antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, Califor-
nia). The protein assay kit was purchased from Pierce Biotechnology (Rockford,
Illinois).
CCK-1 RECEPTOR EXPRESSION
Total RNA was extracted from 5 x 106 cells using TRIzol reagent according
to the manufacturer's instructions. Total RNA (2 Ilg) was reverse transcribed to
complementary DNA using Moloney murine leukemia virus reverse-transcriptase
(RT) and olig-dT, and amplified using deoxynucleotide and Taq polymerase. The
primers for the CCK-1 receptor (340 bp) were 5'-CCTACGACACCGCCTCCGC-3'
(sense) and 5' -TCCGTTCTTTCTTCTCTGCCTCCT-3' (antisense), and the p-actin
primers (271 bp) were 5' -CTACAATGAGCTGCCTGTGGC-3' (sense) and
5' -CAGGTCCAGACGCAGGATGGC-3' (antisense). The PCR procedure consisted
of an initial denaturation at 94°C for 5 minutes, followed by 35 cycles at 94°C for
1 minute, 56°C for 1 minute, and 72°C for 30 seconds. All PCR products underwent
electrophoresis in a 2% agarose gel containing ethidium bromide. Mia PaCa-2 cells
(1.0 x 106 cells) were added with 10 III of CCK-1 receptor monoclonal antibody.
The fixed cells were then resuspended in phosphate-buffered saline (PBS) followed by
30-minute incubation at room temperature and analysis by flow cytornetry.
MIA PACA-2 CELL VIABILITY ASSAY
Viability of the Mia PaCa-2 cells was determined by MTT assay. Mia PaCa-2 cells
(2.0 x 105 cells/ml) were incubated with CCK-8S (10-9 , 10-8, or 10-7 mol/l) or lor-
glumide (10-5, 10-4, or 10-3 mol/l) for 24, 48, and 72 hours in 96-well plates. Un-
treated cells were used as controls. An aliquot of 10 III MTT (5 mg/ml) was then
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added to each well for an additional 4 hours. The reaction was stopped by adding 150 ul,
of dimethyl sulfoxide, and the optical density was measured at 570 nm.
CELL CYCLE AND APOPTOSIS ANALYSIS
Cells were treated for 48 hours with CCK-8S (10-9, 10-8 mol/L) or lorglumide
(10-5, 10-4 mol/L). Untreated cells were used for the control group. Cells were then
washed twice with ice-cold PBS and fixed in 70% ethanol for 18 hours. The fixed cells
were then resuspended in PBSand treated with 5 mg/mL ribonuclease A for 10 minutes.
Finally, propidium iodide wasadded, followed by 30-minute incubation at room tempera-
ture and then analysis by flowcyrornerry, Meanwhile, quantitative assessment of apoptotic
cells induced by lorglumide was made by TUNEL using an in situ cell death.
BOYDEN CHAMBER ASSAY
To eliminate the proliferation influence caused by the drug, cells were treated with
CCK-8S (10-9 mol/L) and lorglumide (10-5 mol/L) for 24 hours for the Boyden cham-
ber assay and Western blot. Modified Boyden chambers with filter inserts (pore size,
8 urn) coated with Matrigel in 24-well dishes were used. Approximately 2.5 x
104 cells in 100 pL of complete DMEM medium were placed in the upper chamber,
and 1 mL of the same medium was placed in the lower chamber. After a 24-hour
culture, cells were fixed in methanol for 15 minutes and then stained with 0.05%
crystal violet in PBS for 15 minutes. Cells on the upper side of the filters were re-
moved with cotton-tipped swabs. Cells that had invaded into the lower side of the
filter were then stained with hematoxylin and eosin and microscopically observed and
counted in 5 fields of view at 200x magnification. The invasive activity of cancer cells
was expressed as the mean number of cells that invaded the lower side of the filter.
WESTERN BLOTTING
Cell extracts were prepared in radioimmunoprecipitation assay buffer (150 mM
sodium chloride, 0.1 % sodium dodecyl sulfate [SDS}, 0.5% sodium deoxycholate, 1%
Nonidet P-40, and 50 mM tris[hydroxymethy1]aminomethane [pH 8.0}), with the
addition of 2 mM phenylmethylsulfonyl fluoride. Lysis buffer was freshly prepared
and added to rransected cells in 6-well plates (100 pLiwell) on ice, which were then
incubated for 10 minutes. Protein concentrations were determined by protein assay
kit. Equal amounts of protein (10 pg per condition) were boiled for 10 minutes in
loading buffer before being separated on 15% SDS-polyacrylamide gels. Separated
proteins were transferred to polyvinylidene difluoride membranes at 100 V for 1 hour
before membrane blocking in 5% skim milk powder in PBS with 0.1 % Tween 20.
Ami-MMP-2 and secondary antibodies were diluted to 1/1000 in PBS with 0.1%
Tween 20 and incubated for 60 minutes at room temperature with 3 washes between
each step. Protein bands were visualized by enhanced chemiluminescence.
STATISTICAL ANALYSIS
All experiments were repeated at least 3 times, and investigators were blinded to
the study group. Data are reported as mean (SD), and the statistical significance of
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differences between the groups was determined by applying l-way ANOVA, followed
by the Fisher least significant difference. P < 0.05 was considered statistically signifi-
cant. These analyses were performed using SPSS version 13.0 software (SPSS Inc.,
Chicago, Illinois).
RESULTS
CCK-1 RECEPTOR EXPRESSION
A 340-bp long fragment was detected by RT-PCR, indicating the expression of
CCK-l receptor in Mia PaCa-2 cells (Figure lA). Meanwhile, flow cytometry verified
the presence of CCK-l receptor on the membrane surface of Mia PaCa-2 cells at the
protein level (Figure IB).
MIA PACA-2 CELL VIABILITY ASSAY
Mia PaCa-2 cells were incubated in the presence of increasing concentrations of
CCK-8S 00-9 to 10-7 rnol/L) and lorglumide 00-5 to 10-3 rnol/L) for 24 to 72 hours
(Figure 2A, Figure 2B, Table I, Table II). Compared with the control group (70.2%
[1.5%}), CCK-8S promoted cell proliferation at 48 hours (85.1% [l.7%}) at a con-
centration of 10-8 rnol/L (P = 0.039). The lorglumide group significantly inhibited
cell proliferation (52.1 % [1.8%}) at a concentration of 10-4 mol/L (P = 0.002 vs con-
trol). No obvious growth change was found with low drug concentrations in the
24-hour treatment group.
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Figure 1. (A) Reverse transcriptase polymerase chain reaction analysis in human pan-
creatic adenocarcinoma cells, Mia PaCa-2, on cholecystokinin (CCK)-1 receptor
mRNA expression (J3-actin was a loading control); and (B) membrane receptor
expression of CCK-1 receptor protein detected by flow cytometry analysis in
Mia PaCa-2 cells. AU = arbitrary units.
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Figure 2. Human pancreatic adenocarcinoma, Mia PaCa-2 cell viability (mean [SO])
assessed by 3-[4,S-dimethylthiazol-2-yl]-2,S-diphenyltetrazolium bromide assay:
effects of 24- to 72-hour incubation with (A) 10-9 to 10-7 mOI/L cholecystokinin
(CCK)-85; or (B) 10-5 to 10-3 mOI/L lorglumide. *p < 0.05 versus the control
group.
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Table I. Cell cultures treated with cholecystokinin (CCK)-8S determined by 3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyltetrazolium bromide test. Data are mean (SO) percent.
CCK-8S Concentration
Test Duration
24 Hours
48 Hours
72 Hours
10-9 moljL
70.3 (2.1)
78.9 (3.7)*
80.7 (1.4)*
10-8 moljL
75.2 (3.5)
85.1 (1.7)
86.9 (0.6)*
10-7 moljL
75.7 (1.2)
85.0 (0.9)
87.2 (0.4)*
Control
68.1 (2.6)
70.2 (1.5)
72.6 (3.4)
*p < 0.05 versus the control group.
CELL CYCLE AND ApOPTOSIS CHANGE
After the CCK-8S 00-9 to 10-8 mol/L) and lorglumide 00-5 to 10-4 rnol/L) treat-
ment for 48 hours, the cell cycle was moved forward under CCK-8S treatment (50.5%
[1.7%}) for the increasing proportion of S stage cells, compared with the proportion
of the control cells (42.2% [l.4%}; P = 0.001). Meanwhile, lorglumide (40.3%
[0.9%}) retarded the cell cycle at the GO/G1 stage (Figure 3A, Table III), compared
with the proportion of GO/G1 stage cells of the control group (30.2% [1.1 %}; P =
0.002). After 48 hours of treatment with lorglumide (Figure 3B, Table IV), the
quantitative TUNEL assay showed apoptosis. Compared with the apoptosis index rate
in the control group (3.7% [0.6%}), the rate was significantly higher with the 10-5
05.7% [2.9%}; P = 0.018) and 10-4 rnol/L concentrations (27.1% [3.5%}; P =
0.001).
EFFECTS ON INVASION AND MMP-2 EXPRESSION
To eliminate the proliferation influence caused by the drugs, cells were treated
wirh CCK-8S 00-9 rnol/L) and lorglumide 00-5 mol/L) for 24 hours. The number
of invasion cells observed through Matrigel and MMP-2 expression are shown, re-
specrively (Figure 4A, Figure 4B, Table V). The mean (SD) number of invasion
Table II. Cell cultures treated with lorglumide determined by 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide test. Data are mean (SO) percent.
l.orglumide Concentration
Test Duration 10-5 moljL 10-4 moljL 10-3 moljL Control
24 Hours 66.1 (0.7) 61.0 (1.5)* 60.1 (1.2)* 68.1 (2.6)
48 Hours 65.3 (1.5)* 52.1 (1.8)* 51.7 (1.1)* 70.2 (1.5)
72 Hours 60.9 (2.8)* 51.9 (1.9)* 51.4 (2.8)* 72.6 (3.4)
*p < 0.05 versus the control group.
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Figure 3. (A) Flow cytometry analysis (mean [SO)) showing the effect of 48-hour incuba-
tion with 10-9 to 10-8 mOI/L cholecystokinin (CCK)-85 and 10-5 to 10-4 mOI/L
lorglumide on human pancreatic adenocarcinoma cells, Mia PaCa-2, cycle
change; (8) terminal deoxynucleotidyl transferase mediated deoxyuridine tri-
phosphate nick-end labeling analysis of apoptosis index (mean [SO] percentage
DNA fragmentation) by lorglumide. "P < 0.05 versus the 5 stage cell of the
control group; tp < 0.05 versus the GO/G1 stage cell of the control group;
1'p < 0.05 versus the control group.
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Table III. Cell cycle distribution by flow cytometry in cells treated with cholecystokinin
(CCK) and lorglumide. Data are mean (SO) percent.
CCK-8S Lorglumide
Cell Cycle 10-9 mOI/L 10-8 mol/L 10-5 rnol/L 10-4 rnol/L Control
GO/Gl 26.4 (2.1) 20.7 (2.4) 37.1 (3.1)* 40.3 (0.9)* 30.2 (1.1)
S 47.0 (1.9)* 50.5 (1.7)* 36.8 (2.3) 32.2 (2.8) 42.2 (1.4)
G2/M 26.6 (1.5) 28.8 (2.1) 22.1 (2.2) 27.5 (1.9) 27.6 (1.7)
*p < 0.05 versus the control group.
cells in the CCK-8S group (123.8 [1.7}) increased significantly in comparison with
the control group (102.1 [5.8}; P = 0.005) with elevated MMP-2 expression. Lorglu-
mide was associated with a decreased invasion number (77.6 [l.2}; P = 0.003 vs
control), accompanied by attenuared MMP-2 expression.
DISCUSSION
Owing to the low efficiency of traditional diagnosis and treatment of pancreatic
cancer,2,17 early-stage diagnosis, gene therapy, endocrine therapy, and immunologic
therapy have been highlighted in recent years for a better prognosis. 18 CCK and gastrin
are 2 of the most well-known hormones associated with pancreatic cancer treatment.
Within the past 15 years, there has been an exponential increase in knowledge of their
pharmacology, cell biology, receptors, and roles in physiology and pathologic condi-
tions.l? Interestingly, the research focus has been shifted to gastrointestinal cancer in
recent years.
Our results indicate that the CCK-1 receptor was expressed in Mia PaCa-2 cells.
Moonka er aP6 found that 90% of resected pancreatic cancer samples expressed the
CCK-1 receptor via RT-PCR and in situ hybridization. An increase in the expression
of the CCK-1 receptor is a mechanism by which pancreatic malignancies might gain
a significant growth stimulus.
Evaluated with the results of related studies,2o,21 we believe that the normal con-
centration of CCK works to sustain the body's physiologic function. Once pancreatic
Table IV. Apoptosis test via terminal deoxynucleotide transferase-mediated deoxyuri-
dine triphosphate nick-end labeling in cells treated for 48 hours with lorglu-
mide. Data are mean (SO) percent.
Lorglumide Concentration
Apoptosis index rate
*p < 0.05 versus the control group.
10-5 rnol/L
15.7 (2.9)*
10-4 mOI/L
27.1 (3.5)*
Control
3.7 (0.6)
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Figure 4. (A) Transwell invasion assay (mean [50]) showing the effects of 24-hour incuba-
tion with 10-9 moljL cholecystokinin (CCK)-85 and 10-5 moljL lorglumide on
human pancreatic adenocarcinoma cells, Mia PaCa-2. *P < 0.05 versus the
control group; (B) Western blot analysis in Mia PaCa-2 cells of the effect of
24-hour incubation with 10-9 moljL CCK·85 and 10-5 moljL lorglumide on ma-
trix metalloproteinase (MMP)-2 protein expression: column 1, control Mia
PaCa-2 cells; column 2, Mia PaCa-2 cells cultured with CCK-85; column 3, Mia
PaCa-2 cells cultured with lorglumide (/3-actinwas a loading control).
Table V. Invasion cell number by transwell invasion assay in human pancreatic adeno-
carcinoma cell line Mia PaCa-2 cells treated with cholecystokinin (CCK)-85 or
lorglumide. Data are mean (SO).
Invasion cells
CCK-8S 10-8 moljL
123.8 (1.7)*
Lorglumide 10-4 moljL
77.6 (1.2)*
Control
102.1 (5.8)
*p < 0.05 versus the control group.
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cancer initiates in the human body, it can cause a high secretion of CCK and high expres-
sion of the CCK recepror.l" Subsequently, the formation of the autocrine loop via the
CCK-CCK-l receptor pathway causes a malignant biological effect.9,21 There are reports
indicating that CCK can promote cell proliferation through different signal pathways such
as the c-fos tumor gene or cyclooxygenase-2 expression in gastrointestinal cancers.22,23
Th e CCK- l receptor belongs to the G-protein coupled receptor family. The com-
bination of ligand and receptor act ivates many effector proteins or secondary messen-
gers such as cyclic adenosine monoph osphare, phospholipase C/A2 , calcium , and
potassium , and then causes relat ive biological effects.24 In our study, CCK-8S was associ-
ated with cell proliferation in dose- and time-dependent manners, and the rati o in the
S stage of the cell cycle increased . Lorglumide was associated with decreased cell pro-
liferation, arrested cell cycle at GO/G 1, and apoptosis.
Apoptosis (type 1 programm ed cell death) is critical for maintaining tissue homeo-
stasis in metazoan organi sms, and its dysregulation underpins the initiation and pro-
gression of cancer." Convent ional chemotherapy and radiotherapy can induce apoptosis
as a secondary consequence of inflicting cell damage. Wi th genetic and biochemical
understanding of the cellular signaling mechanisms, more direct and selective st rategies
targeting CCK receptors that manipulate the apoptotic process in cancer cells are
emerging as potential therapeur ic and diagnostic tools.26-30
CCK-8S was also associated with an increase in the Mia PaCa-2 cells' invasion abil ity
and MMP-2 expression , while lorglumide was associated with the contrary effect .
MMPs are a group of Zinc-depe ndent endopeptidases with different substra te speci-
ficities. They degrade ext racellu lar matr ix and are involved in tumor invasion and
metastasis in various cancers. In pancreatic cancer, MMP -2 expression is upregulat ed
and correlates with tumor metastasis and recurrence.31,32
Our findings suggest that CCK might exert a t rophic action on the Mia PaCa-2
cell line, whil e lorglumide inhibit ed the cell grow th and invasion in vitro. Blockage
of the CCK-CCK- l recep tor pathway wi th lorglumide mi ght be a strategy for fu tur e
pancreat ic cancer treatment .
STUDY LIMITATIONS
The present study was only an experiment in vitro. More evidence is needed from
in vivo and clinical treatment testing .
CONCLUSIONS
Th e CCK-CCK-l receptor pathway may be involved in the proliferation and invasion
of pancreatic cancer. Further experimenta l studies to explore the mechanism using
CCK-8S and lorglum ide interact ing in vivo are necessary to exploit new research evi-
dence for panc reatic cancer treatment.
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